HomeTechHealthKetamine Clinic in Japan for Inbound Medical Treatment: Nagoya Anesthesia Clinic

Ketamine Clinic in Japan for Inbound Medical Treatment: Nagoya Anesthesia Clinic

Logo

NAGOYA, Japan–(BUSINESS WIRE)–Nov. 14, 2023

Nagoya Anesthesia Clinic (https://nagoyamasui.com/2-2), located in Nagoya City, Aichi Prefecture, Japan, has initiated inbound medical treatment for treatment-resistant depression, other mental disorders, and intractable chronic pain, utilizing the groundbreaking drug Ketamine. Over the past 15 years, the clinic has provided ketamine therapy through more than 1300 ketamine infusions. Our distinctive approach to addressing pain and depression includes a simultaneous cervical epidural block, with successful implementation in over 250 cases, and hypnotherapy during ketamine infusion. Additionally, the clinic offers innovative procedures such as Echo-Guided Botox treatment for stiff neck and Echo-Guided PRP therapy for tennis elbow.

Ketamine, a widely used general anesthetic with a history dating back over 50 years, has also been employed in the United States for the treatment of mental disorders and chronic pain for the past decade. Unlike conventional medications, which may take time to alleviate symptoms, Ketamine offers rapid relief within hours to up to three weeks of administration. Moreover, it is associated with minimal long-term side effects, making it a promising treatment option.

Drawing on their extensive experience of performing Ketamine infusions for various pain and mental disorders, Nagoya Anesthesia Clinic has established the Ketamine Clinic based on Ketamine's potent analgesic and antidepressant properties. Typically, ketamine infusions are administered in sets of 3 to 6 sessions over a span of 1 to 3 weeks, followed by a maintenance therapy once a month, known for its low incidence of long-term side effects.

Nagoya Anesthesia Clinic is dedicated to provision of exceptional care and innovative treatments to patients in Japan and beyond, welcoming patients for inbound medical treatment of treatment-resistant depression, OCD, PTSD, and intractable chronic pain starting from October 2023. Building on their extensive ketamine infusion experience, the clinic aims to support individuals coping with treatment-resistant conditions through innovative, evidence-based, and compassionate approaches.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231113434750/en/

Contact:

For inquiries, please contact:
JTB Medical & Healthcare:
jmhc_info@j-medical-healthcare.com

- Advertisment -

Most Popular

Recent Comments

Asia News Release